| Sep 18 |
New Data to be Presented from EFTISARC-NEO Phase II Evaluating Novel Triple Combination including Immutep’s Efti in Soft Tissue Sarcoma
|
| Sep 16 |
Immutep’s Efti in Combination with MSD’s KEYTRUDA® Leads to Positive Efficacy with Favourable Safety in First Line Head and Neck Cancer
|
| Aug 20 |
Immutep Announces Late-Breaking Abstract in Head & Neck Cancer Selected for Oral Presentation at ESMO Congress 2024
|
| Aug 14 |
Immutep Announces First Participant Dosed in Phase I Study of IMP761, a First in Class Agonist LAG-3 Antibody
|
| Aug 8 |
Both retail investors who control a good portion of Immutep Limited (ASX:IMM) along with institutions must be dismayed after last week's 10% decrease
|
| Aug 7 |
Immutep to Participate in Upcoming Investor Conferences
|
| Jul 31 |
Immutep Quarterly Activities Report Q4 FY24
|
| Jul 22 |
Immutep Announces Successful Meeting with FDA on Phase III Design in Non-Small Cell Lung Cancer
|
| Jul 17 |
Immutep Receives Regulatory Clearance for Phase I Study of First-in-Class LAG-3 Agonist Antibody Designed to Treat Autoimmune Diseases
|
| Jul 15 |
Immutep (IMMP) Up as Combo Therapy Meets Carcinoma Study Goals
|
